Evidence map›Paper›PMID 41282815›Full record

ArticlemedRxiv : the preprint server for health sciences2025

Divergent T Cell Phenotypes Define Pediatric Crohn's Disease and Ulcerative Colitis.

Leonard Nettey, Hengqi Betty Zheng, Joseph C Devlin, Julie E Horowitz, Sara Rosenbaum, Nathalie Fiaschi, Wei Keat Lim, Kyle Kimler, Christina Adler, Annabelle Lee and 31 more

Abstract readPreprint
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

41 authors.

Leonard NetteyProgram in Immunology, Harvard Medical School, Boston, MA 02115, USA.ORCID 0000-0002-0387-9327
Hengqi Betty ZhengDivision of Gastroenterology and Hepatology, Seattle Children's Hospital and University of Washington, Seattle, WA 98105, USA.ORCID 0000-0003-0575-6475
Joseph C DevlinRegeneron Pharmaceuticals Inc., Tarrytown, NY 10591, USA.
Julie E HorowitzRegeneron Pharmaceuticals Inc., Tarrytown, NY 10591, USA.ORCID 0000-0002-8093-4182
Sara RosenbaumDivision of Gastroenterology, Hepatology, and Nutrition, Boston Children's Hospital, Boston, MA 02115, USA.
Nathalie FiaschiRegeneron Pharmaceuticals Inc., Tarrytown, NY 10591, USA.ORCID 0000-0003-2836-2751
Wei Keat LimRegeneron Pharmaceuticals Inc., Tarrytown, NY 10591, USA.ORCID 0000-0002-6226-2570
Kyle KimlerInstitute for Medical Engineering & Science, Massachusetts Institute of Technology, Cambridge, MA 02142, USA.ORCID 0000-0003-4735-9064
Christina AdlerRegeneron Pharmaceuticals Inc., Tarrytown, NY 10591, USA.ORCID 0009-0005-2557-6246
Annabelle LeeRegeneron Pharmaceuticals Inc., Tarrytown, NY 10591, USA.
Min NiRegeneron Pharmaceuticals Inc., Tarrytown, NY 10591, USA.
Yi WeiRegeneron Pharmaceuticals Inc., Tarrytown, NY 10591, USA.
Peter J EhmannRegeneron Pharmaceuticals Inc., Tarrytown, NY 10591, USA.ORCID 0000-0001-8037-5731
Shane E McCarthyRegeneron Pharmaceuticals Inc., Tarrytown, NY 10591, USA.
Manuel A R FerreiraRegeneron Pharmaceuticals Inc., Tarrytown, NY 10591, USA.ORCID 0000-0001-9059-1825
William GalbavyRegeneron Pharmaceuticals Inc., Tarrytown, NY 10591, USA.
Eli StahlRegeneron Pharmaceuticals Inc., Tarrytown, NY 10591, USA.ORCID 0000-0002-1192-0561
Sokol HaxhinastoRegeneron Pharmaceuticals Inc., Tarrytown, NY 10591, USA.ORCID 0000-0002-7430-3464
Sandra CoetzeeRegeneron Pharmaceuticals Inc., Tarrytown, NY 10591, USA.ORCID 0000-0003-2995-8696
Yoko YabeRegeneron Pharmaceuticals Inc., Tarrytown, NY 10591, USA.
Michael DoboszRegeneron Pharmaceuticals Inc., Tarrytown, NY 10591, USA.
Paula KeskulaDivision of Pediatric Hematology/Oncology, Boston Children's Hospital, Boston, MA 02115, USA.ORCID 0000-0002-0458-9153
Jillian ZavistaskiDivision of Pediatric Hematology/Oncology, Boston Children's Hospital, Boston, MA 02115, USA.
Alexandre AlbaneseDivision of Pediatric Hematology/Oncology, Boston Children's Hospital, Boston, MA 02115, USA.ORCID 0000-0001-7093-574X
Zoë SteierInstitute for Medical Engineering & Science, Massachusetts Institute of Technology, Cambridge, MA 02142, USA.ORCID 0000-0003-1488-7995
Joshua de Sousa CasalProgram in Immunology, Harvard Medical School, Boston, MA 02115, USA.ORCID 0000-0003-2006-3992
Veronika NiederlovaRagon Institute of MGH, MIT, and Harvard, Cambridge, MA 02139, USA.ORCID 0000-0001-8768-9039
Lusine AmbartsumyanDivision of Gastroenterology and Hepatology, Seattle Children's Hospital and University of Washington, Seattle, WA 98105, USA.
Ghassan WahbehDivision of Gastroenterology and Hepatology, Seattle Children's Hospital and University of Washington, Seattle, WA 98105, USA.
David L SuskindDivision of Gastroenterology and Hepatology, Seattle Children's Hospital and University of Washington, Seattle, WA 98105, USA.ORCID 0000-0002-3524-5150
Vanessa MitsialisDivision of Gastroenterology, Hepatology, and Nutrition, Boston Children's Hospital, Boston, MA 02115, USA.ORCID 0000-0002-1186-3616
Sara HamonRegeneron Pharmaceuticals Inc., Tarrytown, NY 10591, USA.ORCID 0000-0002-2413-2302
Stephen M CarpenterDivision of Infectious Diseases and HIV Medicine, Department of Medicine, University Hospitals, Case Western Reserve University School of Medicine, Cleveland, OH 44106, USA.ORCID 0000-0001-9879-327X
Jennifer D HamiltonRegeneron Pharmaceuticals Inc., Tarrytown, NY 10591, USA.
Alex K ShalekProgram in Immunology, Harvard Medical School, Boston, MA 02115, USA.ORCID 0000-0001-5670-8778
Scott B SnapperDivision of Gastroenterology, Hepatology, and Nutrition, Boston Children's Hospital, Boston, MA 02115, USA.ORCID 0000-0003-0267-4247
Matthew A SleemanRegeneron Pharmaceuticals Inc., Tarrytown, NY 10591, USA.ORCID 0009-0001-9591-4723
George D KallioliasRegeneron Pharmaceuticals Inc., Tarrytown, NY 10591, USA.ORCID 0000-0002-4427-8245
Andrea T HooperRegeneron Pharmaceuticals Inc., Tarrytown, NY 10591, USA.ORCID 0000-0003-1131-1229
Jose Ordovas-MontanesProgram in Immunology, Harvard Medical School, Boston, MA 02115, USA.ORCID 0000-0001-5444-5601
Leslie S KeanDivision of Pediatric Hematology/Oncology, Boston Children's Hospital, Boston, MA 02115, USA.ORCID 0000-0003-0475-3926

Funding

Transplant Tolerance in Non-Human PrimatesU19AI051731 · NIAID · UNIVERSITY OF WESTERN ONTARIO · PI LARSEN, CHRISTIAN P. · 2002 to 2022
$54.1M
Medical Scientist Training ProgramT32GM007753 · NIGMS · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI WALENSKY, LOREN DAVID · 1985 to 2021
$50.0M
STRUCTURE-FUNCTION RELATIONSHIPS IN THE ALIMENTARY TRACTP30DK034854 · NIDDK · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI JONATHAN C KAGAN · 1986 to 2026
$32.4M
Medical Scientist Training ProgramT32GM144273 · NIGMS · HARVARD MEDICAL SCHOOL · PI David Shumway Jones, Jacqueline A. Lees · 2022 to 2026
$14.7M
Novel Biologic Therapies for GVHDR01HL095791 · NHLBI · SEATTLE CHILDREN'S HOSPITAL · PI KEAN, LESLIE S · 2010 to 2025
$13.3M
Project 3: Enhanced Costimulation Blockade to Achieve Clinically Relevant Heart Allograft ToleranceP01HL158504 · NHLBI · MASSACHUSETTS GENERAL HOSPITAL · PI PIERSON, RICHARD N · 2021 to 2025
$12.1M
Identifying Immune and Epithelial Network Signatures in Very Early Onset Inflammatory Bowel DiseaseRC2DK122532 · NIDDK · BOSTON CHILDREN'S HOSPITAL · PI KLEIN, CHRISTOPH, MUISE, ALEIXO M · 2020 to 2024
$9.1M
Initiation of immune responses to SARS COV2 in the oral cavity and upper airwayR01DE031928 · NIDCR · UNIVERSITY OF MISSISSIPPI MED CTR · PI GILL DIAMOND, SARAH C GLOVER · 2022 to 2026
$3.8M
Balancing epithelial cell resistance and resilience to respiratory viral infectionsR01HL162642 · NHLBI · BOSTON CHILDREN'S HOSPITAL · PI Jose Manuel Ordovas-Montanes · 2023 to 2026
$3.4M
An integrated multiplexed genomic assay for low input clinical samples1U24AI118672 · NIAID · BROAD INSTITUTE, INC. · PI SHALEK, ALEX K · 2015 to 2019
$2.0M
NHLBI NIH HHS P01 HL158504NHLBI NIH HHS R01 HL095791NHLBI NIH HHS R01 HL162642NIAID NIH HHS U19 AI051731NIAID NIH HHS U24 AI118672NIDCR NIH HHS R01 DE031928NIDDK NIH HHS P30 DK034854NIDDK NIH HHS RC2 DK122532NIGMS NIH HHS T32 GM007753NIGMS NIH HHS T32 GM144273Wellcome Trust
6 · The paper itself

Abstract

Pediatric Inflammatory Bowel Disease (IBD) remains challenging to treat and difficult to prognosticate. Although multiple immune cell types coordinate pathology in both Crohn's disease (CD) and ulcerative colitis (UC), specifying which cell types and cell states portend better or worse response to major IBD treatment strategies, including anti-TNF therapies (the only FDA-approved therapy for pediatric IBD), remains challenging. Here, we present the results of the PREDICT study, which enrolled 79 treatment-naïve pediatric patients at the time of diagnostic endoscopy, enabling a comprehensive transcriptomic, histologic, and serologic analysis of 40 CD patients and 16 UC patients, as well as 23 patients with functional gastrointestinal disorders (FGID) who served as pediatric non-inflamed controls. Leveraging these data, we performed a comprehensive analysis of colonic immunology in each of these clinical conditions. Our results indicate that, within the complex landscape of immune pathology in pediatric CD and UC, there is a coordinated shift across the T

Identifiers

PMID41282815
PMCPMC12633124

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.